Stocks
Funds
Screener
Sectors
Watchlists
MORF

MORF - Morphic Holding Inc Stock Price, Fair Value and News

$56.990.00 (0.00%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

MORF Price Action

MORF RSI Chart

MORF Valuation

MORF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MORF Fundamentals

MORF Revenue

MORF Earnings

MORF Profitability

MORF Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202353.2M35.7M18.1M521.0K
202232.5M45.3M58.1M70.8M
202142.6M38.8M16.1M19.8M
202024.0M31.0M38.0M44.9M
20199.1M14.9M20.7M17.0M
20180003.4M
MORF
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. Its lead product candidate MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation is in Phase 2 clinical trials for the treatment of inflammatory bowel disease. The company's products in pipeline include Next Gen a4ß7 Inhibitors for additional potential GI indications, such as EGIDs, pouchitis, etc.; avß8 for the treatment of Myelofibrosis and solid tumor; and fibronectin integrin for pulmonary hypertensive. In addition, it has a license agreement with Janssen to discover and develop novel integrin therapeutics; collaboration agreement with Schrödinger for integrin targets; and license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications. The company was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEmorphictx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES110